SOURCE: Barrier Therapeutics, Inc.

October 25, 2005 08:00 ET

Barrier Therapeutics to Release Third Quarter Financial Results on November 1, 2005

Company to Host Conference Call at 4:30 p.m. ET on November 1, 2005

PRINCETON, NJ -- (MARKET WIRE) -- October 25, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, is scheduled to release financial results for the third quarter of 2005, on Tuesday, November 1, 2005 at approximately 4:00 p.m. Eastern Time. The Company will sponsor a conference call on November 1st at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors can listen to the call live over the Internet in the investor relations section of the Company's website located at or by dialing 1-888-889-2497 (U.S.) or 1-973-582-2710 (International).


Barrier Therapeutics, Inc. Third Quarter 2005 Corporate Update and Financial Results Conference Call


Tuesday, November 1, 2005, 4:30 p.m. Eastern Time


The investor relations section of the Company's website located at


Live over the Internet -- Simply log on to the web at the address above, or dial 1-888-889-2497 (U.S.) or 1-973-582-2710 (International)

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and recently obtained the Canadian distribution rights for Vaniqa® (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include Vusion™ (formerly known as Zimycan™) for the treatment of diaper dermatitis complicated by candidiasis, which is under FDA review, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site:

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Jane Petrino